Topiramate

Last updated

Topiramate
Topiramate structure.svg
Topiramate 3D.png
Clinical data
Trade names Topamax, Trokendi XR, Qudexy XR, others
Other namesTopiramic acid
AHFS/Drugs.com Monograph
MedlinePlus a697012
License data
Pregnancy
category
  • AU:D
Routes of
administration 		Oral
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 80%
Protein binding 13–17%; 15–41%
Metabolism Liver (20–30%)
Elimination half-life 21 hours
Excretion Urine (70–80%)
Identifiers
  • 2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
ECHA InfoCard 100.129.713 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C12H21NO8S
Molar mass 339.36 g·mol−1
3D model (JSmol)
  • O=S(=O)(OC[C@@]21OC(O[C@H]1[C@@H]3OC(O[C@@H]3CO2)(C)C)(C)C)N
  • InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1 Yes check.svgY
  • Key:KJADKKWYZYXHBB-XBWDGYHZSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Topiramate, sold under the brand name Topamax among others, is a medication used to treat epilepsy and prevent migraines. [9] It has also been used in alcohol dependence and essential tremor. [9] For epilepsy this includes treatment for generalized or focal seizures. [10] It is taken orally (by mouth). [9]

Contents

Common side effects include tingling, feeling tired, loss of appetite, abdominal pain, weight loss, [11] and decreased cognitive function such as trouble concentrating. [9] [10] Serious side effects may include suicide, increased ammonia levels resulting in encephalopathy, and kidney stones. [9] Topiramate can cause birth defects including cleft lip and palate. [12] Risk/benefit should be carefully discussed with the full treatment team. Topiramate is considered "probably compatible" with lactation and is not contraindicated in breastfeeding, though monitoring of the infant for diarrhea or poor weight gain may be considered. [13] [14] The mechanism of action is unclear. [9]

Topiramate was approved for medical use in the United States in 1996. [9] It is available as a generic medication. [10] [15] [16] In 2022, it was the 84th most commonly prescribed medication in the United States, with more than 8 million prescriptions. [17] [18]

Medical uses

A package of topiramate 25mg from Norway Topimax 25mg.jpg
A package of topiramate 25mg from Norway

Topiramate is used to treat epilepsy in children and adults, and it was originally used as an anticonvulsant. [19] In children, it is indicated for the treatment of Lennox-Gastaut syndrome, a disorder that causes seizures and developmental delay. It is most frequently prescribed for the prevention of migraines [19] as it decreases the frequency of attacks. [20] [21] Topiramate is used to treat medication overuse headache and is recommended by the European Federation of Neurological Societies as one of the few medications showing effectiveness for this indication. [22]

Pain

A 2018 review found topiramate of no use in chronic low back pain. [23] Topiramate has not been shown to work as a pain medicine in diabetic neuropathy, the only neuropathic condition in which it has been adequately tested. [24]

Other

One common off-label use for topiramate is in the treatment of bipolar disorder. [25] [26] [27] A review published in 2010 suggested a benefit of topiramate in the treatment of symptoms of borderline personality disorder, however the authors noted that this was based only on one randomized controlled trial and requires replication. [28]

Topiramate has been used as a treatment for alcoholism. [29] The U.S. Veterans Affairs and Department of Defense 2015 guidelines on substance use disorders list topiramate as a "strong for" in its recommendations for alcohol use disorder. [30]

Other uses include treatment of obesity, [31] [32] binge eating disorder, [33] and off-setting weight gain induced by taking antipsychotic medications. [34] [35] In 2012, the combination of phentermine/topiramate was approved in the United States for weight loss.

Adverse effects

People taking topiramate should be aware of the following risks:

Frequency

Adverse effects by incidence: [40] [41] [42] [43]

Very common (>10% incidence) adverse effects include:

Rarely, the inhibition of carbonic anhydrase may be strong enough to cause metabolic acidosis of clinical importance. [44]

The U.S. Food and Drug Administration (FDA) has notified prescribers that topiramate can cause acute myopia and secondary angle closure glaucoma in a small subset of people who take topiramate regularly. [45] The symptoms, which typically begin in the first month of use, include blurred vision and eye pain. Discontinuation of topiramate may halt the progression of the ocular damage and may reverse the visual impairment.

Preliminary data suggests that, as with several other anti-epileptic drugs, topiramate carries an increased risk of congenital malformations. [46] This might be particularly important for women who take topiramate to prevent migraine attacks. In March 2011, the FDA notified healthcare professionals and patients of an increased risk of development of cleft lip and/or cleft palate (oral clefts) in infants born to women treated with Topamax (topiramate) during pregnancy and placed it in Pregnancy Category D. [38]

Cognitive and word-finding difficulties, as they may occur in some patients, may respond to piracetam. [47] [48]

Carbonation dysgeusia (distortion of the sense of taste-sensation of carbonation) may respond to and/or be prevented to with zinc. [49]

Topiramate has been associated with a statistically significant increase in suicidality, [50] and "suicidal thoughts or actions" is now listed as one of the possible side effects of the drug "in a very small number of people, about 1 in 500." [36] [51]

Overdose

Symptoms of acute and acute on chronic exposure to topiramate range from asymptomatic to status epilepticus, including in patients with no seizure history. [52] [53] In children, overdose may also result in hallucinations. [53] Topiramate has been deemed the primary substance that led to fatal overdoses in cases that were complicated by polydrug exposure. [54] The most common signs of overdose are dilated pupils, somnolence, dizziness, psychomotor agitation, and abnormal, uncoordinated body movements. [52] [53] [54]

Interactions

Topiramate has many drug-drug interactions. Some of the most common are listed below:

Pharmacology

Chair-style representation of skeletal formula Topiramate (chair style).svg
Chair-style representation of skeletal formula

The topiramate molecule is a sulfamate modified sugar, more specifically, fructose diacetonide, an unusual chemical structure for a pharmaceutical.

Topiramate is quickly absorbed after oral use. It has a half life of 21 hours and a steady state of the drug is reached in 4 days in patients with normal renal function. [57] Most of the drug (70%) is excreted in the urine unchanged. The remainder is extensively metabolized by hydroxylation, hydrolysis, and glucuronidation. Six metabolites have been identified in humans, none of which constitutes more than 5% of an administered dose.

Several cellular targets have been proposed to be relevant to the therapeutic activity of topiramate. [58] These include (1) voltage-gated sodium channels; (2) high-voltage-activated calcium channels; (3) GABA-A receptors; (4) AMPA/kainate receptors; and (5) carbonic anhydrase isoenzymes. There is evidence that topiramate may alter the activity of its targets by modifying their phosphorylation state instead of by a direct action. [59] The effect on sodium channels could be of particular relevance for seizure protection. Although topiramate does inhibit high-voltage-activated calcium channels, the relevance to clinical activity is uncertain. Effects on specific GABA-A receptor isoforms could also contribute to the antiseizure activity of the drug. Topiramate selectively inhibits cytosolic (type II) and membrane associated (type IV) forms of carbonic anhydrase. The action on carbonic anhydrase isoenzymes may contribute to the drug's side-effects, including its propensity to cause metabolic acidosis and calcium phosphate kidney stones.

Topiramate inhibits maximal seizure activity in electroconvulsive therapy and in pentylenetetrazol-induced seizures as well as partial and secondarily generalized tonic-clonic seizures in the kindling model, findings predictive of a broad spectrum of activities clinically. Its action on mitochondrial permeability transition pores has been proposed as a mechanism. [60]

While many anticonvulsants have been associated with apoptosis in young animals, animal experiments have found that topiramate is one of the very few anticonvulsants [see: levetiracetam, carbamazepine, lamotrigine] that do not induce apoptosis in young animals at doses needed to produce an anticonvulsant effect. [61]

Detection in body fluids

Blood, serum, or plasma topiramate concentrations may be measured using immunoassay or chromatographic methods to monitor therapy, confirm a diagnosis of poisoning in hospitalized patients, or to assist in a medicolegal death investigation. Plasma levels are usually less than 10 mg/L during therapeutic administration, but can range from 10 to 150 mg/L in overdose victims. [62] [63] [64]

History

Topiramate was discovered in 1979 by Bruce E. Maryanoff and Joseph F. Gardocki during their research work at McNeil Pharmaceuticals. [65] [66] Topiramate was first sold in 1996. [67] Mylan Pharmaceuticals was granted final approval by the FDA for the sale of generic topiramate in the United States and the generic version was made available in September 2006. [68] The last patent for topiramate in the U.S. was for use in children and expired on 28 February 2009. [69]

Research

Topiramate is being studied as a potential treatment for post-traumatic stress disorder (PTSD). [70]

There is some evidence for the use of topiramate in the management of cravings related to withdrawal from dextromethorphan. [71]

A 2023 systematic review of seizure treatment for infants aged 1 to 36 months identified three studies that evaluated the use of topiramate. Though its adverse effects including upper respiratory tract infection and loss of appetite were rarely severe enough for the medication to be discontinued in this age group, its effectiveness in reducing seizures was inconclusive. The available research suffers from small sample sizes, inconsistent findings, and inadequate comparison groups. [72]

Related Research Articles

<span class="mw-page-title-main">Valproate</span> Medication used for epilepsy, bipolar disorder and migraine

Valproate are medications primarily used to treat epilepsy and bipolar disorder and prevent migraine headaches. They are useful for the prevention of seizures in those with absence seizures, partial seizures, and generalized seizures. They can be given intravenously or by mouth, and the tablet forms exist in both long- and short-acting formulations.

Anticonvulsants are a diverse group of pharmacological agents used in the treatment of epileptic seizures. Anticonvulsants are also increasingly being used in the treatment of bipolar disorder and borderline personality disorder, since many seem to act as mood stabilizers, and for the treatment of neuropathic pain. Anticonvulsants suppress the excessive rapid firing of neurons during seizures. Anticonvulsants also prevent the spread of the seizure within the brain.

<span class="mw-page-title-main">Lamotrigine</span> Medication used for bipolar disorder, epilepsy, & many seizure disorders

Lamotrigine, sold under the brand name Lamictal among others, is a medication used to treat epilepsy and stabilize mood in bipolar disorder. For epilepsy, this includes focal seizures, tonic-clonic seizures, and seizures in Lennox-Gastaut syndrome. In bipolar disorder, lamotrigine has not been shown to reliably treat acute depression in any groups except for the severely depressed; but for patients with bipolar disorder who are not currently symptomatic, it appears to reduce the risk of future episodes of depression.

<span class="mw-page-title-main">Oxcarbazepine</span> Anticonvulsant medication

Oxcarbazepine, sold under the brand name Trileptal among others, is a medication used to treat epilepsy. For epilepsy it is used for both focal seizures and generalized seizures. It has been used both alone and as add-on therapy in people with bipolar disorder who have had no success with other treatments. It is taken by mouth.

<span class="mw-page-title-main">Clonazepam</span> Benzodiazepine medication

Clonazepam, sold under the brand name Klonopin among others, is a benzodiazepine medication used to prevent and treat anxiety disorders, seizures, bipolar mania, agitation associated with psychosis, obsessive–compulsive disorder (OCD), and akathisia. It is a long-acting tranquilizer of the benzodiazepine class. It possesses anxiolytic, anticonvulsant, sedative, hypnotic, and skeletal muscle relaxant properties. It is typically taken orally but is also used intravenously. Effects begin within one hour and last between eight and twelve hours in adults.

<span class="mw-page-title-main">Tiagabine</span> Anticonvulsant medication

Tiagabine is an anticonvulsant medication produced by Cephalon that is used in the treatment of epilepsy. The drug is also used off-label in the treatment of anxiety disorders and panic disorder.

<span class="mw-page-title-main">Primidone</span> Barbiturate medication used to treat seizures and tremors

Primidone, sold under various brand names, is a barbiturate medication that is used to treat partial and generalized seizures and essential tremors. It is taken by mouth.

<span class="mw-page-title-main">Zonisamide</span> Chemical compound

Zonisamide, sold under the brand name Zonegran among others, is a medication used to treat the symptoms of epilepsy and Parkinson's disease. Chemically it is a sulfonamide. It serves as an anticonvulsant used primarily as an adjunctive therapy in adults with Parkinson's disease, partial-onset seizures; infantile spasm, mixed seizure types of Lennox–Gastaut syndrome, myoclonic and generalized tonic clonic seizure. Despite this it is also sometimes used as a monotherapy for partial-onset seizures.

<span class="mw-page-title-main">Stiripentol</span> Anticonvulsant medication

Stiripentol, sold under the brand name Diacomit, is an anticonvulsant medication used for the treatment of Dravet syndrome - a serious genetic brain disorder.

<span class="mw-page-title-main">Felbamate</span> Chemical compound

Felbamate is an anticonvulsant used in the treatment of epilepsy. It is used to treat partial seizures in adults and partial and generalized seizures associated with Lennox–Gastaut syndrome in children. However, an increased risk of potentially fatal aplastic anemia and/or liver failure limit the drug's usage to severe refractory epilepsy.

<span class="mw-page-title-main">Carbonic anhydrase inhibitor</span> Class of pharmaceuticals

Carbonic anhydrase inhibitors are a class of pharmaceuticals that suppress the activity of carbonic anhydrase. Their clinical use has been established as anti-glaucoma agents, diuretics, antiepileptics, in the management of mountain sickness, gastric and duodenal ulcers, idiopathic intracranial hypertension, neurological disorders, or osteoporosis.

<span class="mw-page-title-main">Sultiame</span> Chemical compound

Sultiame is a sulfonamide and inhibitor of the enzyme carbonic anhydrase. It is used as an anticonvulsant and in recent studies showed promise in reducing sleep disordered breathing and other symptoms of obstructive sleep apnea (OSA).

<span class="mw-page-title-main">Rufinamide</span> Chemical compound

Rufinamide is an anticonvulsant medication. It is used in combination with other medication and therapy to treat Lennox–Gastaut syndrome and various other seizure disorders. Rufinamide, a triazole derivative, was developed in 2004 by Novartis Pharma, AG, and is manufactured by Eisai.

<span class="mw-page-title-main">Lacosamide</span> Anticonvulsant and analgesic medication

Lacosamide, sold under the brand name Vimpat among others, is a medication used for the treatment of partial-onset seizures and primary generalized tonic-clonic seizures. It is used by mouth or intravenously.

<span class="mw-page-title-main">Ganaxolone</span> Chemical compound

Ganaxolone, sold under the brand name Ztalmy, is a medication used to treat seizures in people with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder. Ganaxolone is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator.

<span class="mw-page-title-main">Eslicarbazepine acetate</span> Anticonvulsant medication

Eslicarbazepine acetate (ESL), sold under the brand names Aptiom and Zebinix among others, is an anticonvulsant medication approved for use in Europe and the United States as monotherapy or as additional therapy for partial-onset seizures epilepsy.

<span class="mw-page-title-main">Phentermine/topiramate</span> Obesity medication

Phentermine/topiramate, sold under the brand names Qsymia or QSIVA, is a combination drug of phentermine and topiramate used to treat obesity. It is used together with dietary changes and exercise. If less than 3% weight loss is seen after 3 months it is recommended the medication be stopped. The weight loss is modest. Effects on heart related health problems or death is unclear.

<span class="mw-page-title-main">JNJ-26990990</span> Experimental anticonvulsant drug

JNJ-26990990 is a broad-spectrum anticonvulsant drug currently under development by Janssen Pharmaceutica as a second-generation follow-up to the marketed drug topiramate. It was designed to have the same anticonvulsant effects as topiramate, but without the side effects associated with topiramate's carbonic anhydrase inhibition. It also has potential use in the treatment of inflammatory pain, neuropathic pain, and depression.

<span class="mw-page-title-main">JNJ-26489112</span> Chemical compound

JNJ-26489112 is an anticonvulsant drug being developed by Johnson & Johnson for the treatment of epilepsy. JNJ-26489112 was designed as a successor to topiramate. It is expected to have fewer side effects than topiramate because it lacks activity against carbonic anhydrase.

Antimanic drugs are psychotropic drugs that are used to treat symptoms of mania. Though there are different causes of mania, the majority is caused by bipolar disorder, therefore antimanic drugs are mostly similar to drugs treating bipolar disorder. Since 1970s, antimanic drugs have been used specifically to control the abnormal elevation of mood or mood swings during manic episodes. One purpose of antimanic drugs is to alleviate or shorten the duration of an acute mania. Another objective is to prevent further cycles of mania and maintain the improvement achieved during the acute episode. The mechanism of antimanic drugs has not yet been fully known, it is proposed that they mostly affect chemical neurotransmitters in the brain. However, the usage of antimanic drugs should be consulted with a doctor or pharmacist due to their side effects and interactions with other drugs and food.

References

  1. ↑ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
  2. ↑ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 October 2023.
  3. ↑ "Trokendi XR- topiramate capsule, extended release". DailyMed. Archived from the original on 8 November 2021. Retrieved 8 November 2021.
  4. ↑ "Topamax- topiramate tablet, coated Topamax- topiramate capsule, coated pellets". DailyMed. Archived from the original on 8 November 2021. Retrieved 8 November 2021.
  5. ↑ "Qsymia- phentermine and topiramate capsule, extended release". DailyMed. Archived from the original on 26 October 2021. Retrieved 8 November 2021.
  6. ↑ "Qudexy XR- topiramate capsule, extended release". DailyMed. Archived from the original on 8 November 2021. Retrieved 8 November 2021.
  7. ↑ "Eprontia - topiramate solution". DailyMed. Archived from the original on 19 December 2021. Retrieved 19 December 2021.
  8. ↑ "Active substance(s): topiramate" (PDF). List of nationally authorised medicinal products. European Medicines Agency. September 2022. Archived (PDF) from the original on 6 September 2022. Retrieved 6 September 2022.
  9. 1 2 3 4 5 6 7 "Topiramate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 6 March 2019. Retrieved 5 March 2019.
  10. 1 2 3 British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 328. ISBN   9780857113382.
  11. ↑ "Topiramate Side Effects: Common, Severe, Long Term". Drugs.com. Archived from the original on 10 April 2021. Retrieved 3 August 2021.
  12. ↑ "FDA Drug Safety Communication: Risk of oral clefts in children born to mothers taking Topamax (topiramate)". FDA. 18 June 2019.
  13. ↑ Health MC (10 August 2022). "Essential Reads: Breastfeeding and Anti-Epileptic Drugs - MGH Center for Women's Mental Health" . Retrieved 27 December 2023.
  14. ↑ "Topiramate", Drugs and Lactation Database (LactMed®), Bethesda (MD): National Institute of Child Health and Human Development, 2006, PMID   30000318 , retrieved 27 December 2023
  15. ↑ "Competitive Generic Therapy Approvals". U.S. Food and Drug Administration (FDA). 29 June 2023. Archived from the original on 29 June 2023. Retrieved 29 June 2023.
  16. ↑ "First Generic Drug Approvals 2023". U.S. Food and Drug Administration (FDA). 30 May 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
  17. ↑ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  18. ↑ "Topiramate Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
  19. 1 2 "Topamax Prescribing Information" (PDF). United States Food and Drug Administration. Archived (PDF) from the original on 24 April 2016. Retrieved 11 April 2016.
  20. ↑ Linde M, Mulleners WM, Chronicle EP, McCrory DC (June 2013). "Topiramate for the prophylaxis of episodic migraine in adults". The Cochrane Database of Systematic Reviews. 6 (6): CD010610. doi:10.1002/14651858.CD010610. PMC   7388931 . PMID   23797676.
  21. ↑ Ferrari A, Tiraferri I, Neri L, Sternieri E (September 2011). "Clinical pharmacology of topiramate in migraine prevention". Expert Opinion on Drug Metabolism & Toxicology. 7 (9): 1169–1181. doi:10.1517/17425255.2011.602067. PMID   21756204. S2CID   207491096.
  22. ↑ Evers S, Jensen R (September 2011). "Treatment of medication overuse headache--guideline of the EFNS headache panel". European Journal of Neurology. 18 (9): 1115–1121. doi: 10.1111/j.1468-1331.2011.03497.x . PMID   21834901. S2CID   2698885.
  23. ↑ Enke O, New HA, New CH, Mathieson S, McLachlan AJ, Latimer J, et al. (July 2018). "Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis". CMAJ. 190 (26): E786–E793. doi:10.1503/cmaj.171333. PMC   6028270 . PMID   29970367.{{cite journal}}: CS1 maint: overridden setting (link)
  24. ↑ Wiffen PJ, Derry S, Lunn MP, Moore RA (August 2013). Derry S (ed.). "Topiramate for neuropathic pain and fibromyalgia in adults". The Cochrane Database of Systematic Reviews. 2013 (8): CD008314. doi:10.1002/14651858.CD008314.pub3. PMC   8406931 . PMID   23996081. Archived from the original on 31 March 2014. Retrieved 6 September 2013.
  25. ↑ Arnone D (February 2005). "Review of the use of Topiramate for treatment of psychiatric disorders". Annals of General Psychiatry. 4 (1): 5. doi: 10.1186/1744-859X-4-5 . PMC   1088011 . PMID   15845141.
  26. ↑ Vasudev K, Macritchie K, Geddes J, Watson S, Young A (January 2006). Young AH (ed.). "Topiramate for acute affective episodes in bipolar disorder". The Cochrane Database of Systematic Reviews (1): CD003384. doi:10.1002/14651858.CD003384.pub2. PMID   16437453.
  27. ↑ Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, et al. (October 2011). "Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis". Lancet. 378 (9799): 1306–1315. doi:10.1016/s0140-6736(11)60873-8. PMID   21851976. S2CID   25512763.{{cite journal}}: CS1 maint: overridden setting (link)
  28. ↑ Lieb K, Völlm B, Rücker G, Timmer A, Stoffers JM (January 2010). "Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials". The British Journal of Psychiatry. 196 (1): 4–12. doi: 10.1192/bjp.bp.108.062984 . PMID   20044651.
  29. ↑ Johnson BA, Ait-Daoud N (2010). "Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients". Current Pharmaceutical Design. 16 (19): 2103–2112. doi:10.2174/138161210791516404. PMC   3063512 . PMID   20482511.
  30. ↑ "VA/DoD Clinical Practice Guideline for the management of substance use disorders" (PDF). healthquality.va.gov. 31 December 2015. Archived (PDF) from the original on 31 August 2017. Retrieved 30 August 2017.
  31. ↑ Verrotti A, Scaparrotta A, Agostinelli S, Di Pillo S, Chiarelli F, Grosso S (August 2011). "Topiramate-induced weight loss: a review". Epilepsy Research. 95 (3): 189–199. doi:10.1016/j.eplepsyres.2011.05.014. PMID   21684121. S2CID   30103553.
  32. ↑ Kramer CK, Leitão CB, Pinto LC, Canani LH, Azevedo MJ, Gross JL (May 2011). "Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials". Obesity Reviews. 12 (5): e338–e347. doi: 10.1111/j.1467-789X.2010.00846.x . PMID   21438989. S2CID   24358798.
  33. ↑ "Topiramate for Binge Eating Disorder". wa.kaiserpermanente.org. Archived from the original on 3 August 2021. Retrieved 3 August 2021.
  34. ↑ Hahn MK, Cohn T, Teo C, Remington G (January 2013). "Topiramate in schizophrenia: a review of effects on psychopathology and metabolic parameters". Clinical Schizophrenia & Related Psychoses. 6 (4): 186–196. doi:10.3371/CSRP.HACO.01062013. PMID   23302448.
  35. ↑ Mahmood S, Booker I, Huang J, Coleman CI (February 2013). "Effect of topiramate on weight gain in patients receiving atypical antipsychotic agents". Journal of Clinical Psychopharmacology. 33 (1): 90–94. doi:10.1097/JCP.0b013e31827cb2b7. PMID   23277264. S2CID   26085987.
  36. 1 2 "Possible Side Effects - Topamax (topiramate)". Topamax.xom. Archived from the original on 28 January 2011. Retrieved 17 October 2014.
  37. ↑ "Topamax (topiramate) tablets and sprinkle capsules". Fda.gov. Archived from the original on 12 January 2017. Retrieved 17 October 2014.
  38. 1 2 "Risk of oral clefts in children born to mothers taking Topamax (topiramate)". FDA Drug Safety Communication. Fda.gov. 6 January 2011. Archived from the original on 24 April 2019. Retrieved 11 July 2013.
  39. ↑ "Seizures and Epilepsy in Children". www.hopkinsmedicine.org. 8 August 2021. Retrieved 19 July 2023.
  40. ↑ "Topamax Tablets and Sprinkle Capsules PRODUCT INFORMATION" (PDF). TGA eBusiness Services. JANSSEN-CILAG Pty Ltd. 30 May 2013. Archived from the original on 29 March 2019. Retrieved 18 November 2013.
  41. ↑ "topiramate (Rx) - Topamax, Trokendi XR". Medscape Reference. WebMD. Archived from the original on 19 May 2019. Retrieved 18 November 2013.
  42. ↑ "Topiramate 100 mg film-coated Tablets". electronic Medicines Compendium. Sandoz Limited. 6 March 2013. Archived from the original on 21 May 2014. Retrieved 18 November 2013.
  43. ↑ "TOPIRAMATE ( topiramate ) tablet TOPIRAMATE ( topiramate ) tablet [Torrent Pharmaceuticals Limited]". DailyMed. Torrent Pharmaceuticals Limited. August 2011. Archived from the original on 20 May 2014. Retrieved 18 November 2013.
  44. ↑ Mirza N, Marson AG, Pirmohamed M (November 2009). "Effect of topiramate on acid-base balance: extent, mechanism and effects". British Journal of Clinical Pharmacology. 68 (5): 655–661. doi:10.1111/j.1365-2125.2009.03521.x. PMC   2791971 . PMID   19916989.
  45. ↑ Hulihan J (2001). "IMPORTANT DRUG WARNING" (PDF). FDA MedWatch. Ortho-McNeil Pharmaceutical. Archived from the original (PDF) on 13 January 2017. Retrieved 11 June 2018.
  46. ↑ Hunt S, Russell A, Smithson WH, Parsons L, Robertson I, Waddell R, et al. (July 2008). "Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register". Neurology. 71 (4): 272–276. doi:10.1212/01.wnl.0000318293.28278.33. PMID   18645165. S2CID   13562052.{{cite journal}}: CS1 maint: overridden setting (link)
  47. ↑ Berthier, M.L. and Dávila, G., 2023. Pharmacotherapy for post-stroke aphasia: what are the options?. Expert Opinion on Pharmacotherapy, (just-accepted).
  48. ↑ Cumbo, E. and Ligori, L.D., 2010. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer’s disease. Epilepsy & Behavior, 17(4), pp.461-466.
  49. ↑ Charbonneau, M., Doyle-Campbell, C., Laskey, C. and Capoccia, K., 2020. Carbonation dysgeusia associated with topiramate. American Journal of Health-System Pharmacy, 77(14), pp.1113-1116.
  50. ↑ "Suicidality and Antiepileptic Drugs" (PDF). Food and Drug Administration . Archived from the original on 10 May 2017. Retrieved 11 July 2013.
  51. ↑ "Topiramate". PubMed Health. National Center for Biotechnology Information, U.S. National Library of Medicine. Archived from the original on 5 August 2010.
  52. 1 2 Wiśniewski M, Łukasik-Głebocka M, Anand JS (April 2009). "Acute topiramate overdose--clinical manifestations". Clinical Toxicology. 47 (4): 317–320. doi:10.1080/15563650601117954. PMID   19514879. S2CID   205901501.
  53. 1 2 3 Wills B, Reynolds P, Chu E, Murphy C, Cumpston K, Stromberg P, et al. (September 2014). "Clinical outcomes in newer anticonvulsant overdose: a poison center observational study". Journal of Medical Toxicology. 10 (3): 254–260. doi:10.1007/s13181-014-0384-5. PMC   4141920 . PMID   24515527.
  54. 1 2 Lofton AL, Klein-Schwartz W (November 2005). "Evaluation of toxicity of topiramate exposures reported to poison centers". Human & Experimental Toxicology. 24 (11): 591–595. Bibcode:2005HETox..24..591L. doi:10.1191/0960327105ht561oa. PMID   16323576. S2CID   37784043.
  55. 1 2 Sweetman SC, ed. (2009). "Sex hormones and their modulators". Martindale: The complete drug reference (36th ed.). London: Pharmaceutical Press. p. 2068. ISBN   978-0-85369-840-1.
  56. ↑ "TOPAMAX (topiramate) Tablets Approved Labeling Text" (PDF). Ortho-McNeil Pharmaceutical. U.S. Food and Drug Administration. 29 June 2005. p. 14. Archived from the original (PDF) on 5 February 2007.
  57. ↑ "FDA Data on Topamax" (PDF). Archived (PDF) from the original on 6 August 2021. Retrieved 6 August 2021.
  58. ↑ Porter RJ, Dhir A, Macdonald RL, Rogawski MA (2012). "Mechanisms of action of antiseizure drugs". Handb Clin Neurol. Handbook of Clinical Neurology. Vol. 108. pp. 663–681. doi:10.1016/B978-0-444-52899-5.00021-6. ISBN   9780444528995. PMID   22939059. Archived from the original on 22 June 2017. Retrieved 22 May 2014.
  59. ↑ Meldrum BS, Rogawski MA (January 2007). "Molecular targets for antiepileptic drug development". Neurotherapeutics. 4 (1): 18–61. doi:10.1016/j.nurt.2006.11.010. PMC   1852436 . PMID   17199015.
  60. ↑ Kudin AP, Debska-Vielhaber G, Vielhaber S, Elger CE, Kunz WS (December 2004). "The mechanism of neuroprotection by topiramate in an animal model of epilepsy". Epilepsia. 45 (12): 1478–1487. doi: 10.1111/j.0013-9580.2004.13504.x . PMID   15571505. S2CID   7067509.
  61. ↑ Czuczwar K, Czuczwar M, Cieszczyk J, Gawlik P, Luszczki JJ, Borowicz KK, et al. (2004). "[Neuroprotective activity of antiepileptic drugs]". Przeglad Lekarski. 61 (11): 1268–1271. PMID   15727029.
  62. ↑ Goswami D, Kumar A, Khuroo AH, Monif T, Rab S (November 2009). "Bioanalytical LC-MS/MS method validation for plasma determination of topiramate in healthy Indian volunteers". Biomedical Chromatography. 23 (11): 1227–41. doi:10.1002/bmc.1273. PMID   19593736.
  63. ↑ Brandt C, Elsner H, Füratsch N, Hoppe M, Nieder E, Rambeck B, et al. (June 2010). "Topiramate overdose: a case report of a patient with extremely high topiramate serum concentrations and nonconvulsive status epilepticus". Epilepsia. 51 (6): 1090–1093. doi:10.1111/j.1528-1167.2009.02395.x. PMID   19889015. S2CID   35752877.{{cite journal}}: CS1 maint: overridden setting (link)
  64. ↑ Baselt R (2008). Disposition of Toxic Drugs and Chemicals in Man (8th ed.). Foster City, CA: Biomedical Publications. pp. 1567–1569.
  65. ↑ Maryanoff BE, Nortey SO, Gardocki JF, Shank RP, Dodgson SP (May 1987). "Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate and related compounds". Journal of Medicinal Chemistry. 30 (5): 880–887. doi:10.1021/jm00388a023. PMID   3572976.
  66. ↑ Maryanoff BE, Costanzo MJ, Nortey SO, Greco MN, Shank RP, Schupsky JJ, et al. (April 1998). "Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives". Journal of Medicinal Chemistry. 41 (8): 1315–1343. doi:10.1021/jm970790w. PMID   9548821.{{cite journal}}: CS1 maint: overridden setting (link)
  67. ↑ Pitkänen A, Schwartzkroin PA, Moshé SL (2005). Models of Seizures and Epilepsy. Burlington: Elsevier. p. 539. ISBN   9780080457024. Archived from the original on 8 September 2017. Retrieved 17 September 2017.
  68. ↑ Waknine Y (22 September 2006). "First-Time Generic Approvals: Seasonale, Imodium Advanced, and Topamax". Medscape.com. Archived from the original on 20 May 2013. Retrieved 11 July 2013.
  69. ↑ "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations". Accessdata.fda.gov. Archived from the original on 25 April 2016. Retrieved 17 October 2014.
  70. ↑ Andrus MR, Gilbert E (November 2010). "Treatment of civilian and combat-related posttraumatic stress disorder with topiramate". The Annals of Pharmacotherapy. 44 (11): 1810–1816. doi:10.1345/aph.1P163. PMID   20923947. S2CID   12137726.
  71. ↑ Roy AK 3rd, Hsieh C, Crapanzano K. Dextromethorphan Addiction Mediated Through the NMDA System: Common Pathways With Alcohol? J Addict Med. 2015 Nov-Dec;9(6):499-501. doi: 10.1097/ADM.0000000000000152. PMID 26441400.
  72. ↑ Treadwell JR, Wu M, Tsou AY (25 October 2022). Management of Infantile Epilepsies (Report). Agency for Healthcare Research and Quality. doi:10.23970/ahrqepccer252.

Commons-logo.svg Media related to Topiramate at Wikimedia Commons

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.